Milloni Doshi, a 25-year-old student from India who is supposed to start her master’s degree this fall at Columbia University’s School of International and Public Affairs, has a problem.
Although Ms. Doshi has been vaccinated against the coronavirus, she received two doses of Covaxin, which is made by an Indian manufacturer and is not currently approved by the World Health Organization, as required by the university.
Columbia has told her she will need to be revaccinated with a different vaccine once she arrives on campus, but no one can say for sure if it is safe to do so.
